Đang chuẩn bị nút TẢI XUỐNG, xin hãy chờ
Tải xuống
Ramucirumab monotherapy as a second-line treatment for advanced gastric cancer (AGC) prolongs survival compared to the best supportive care. However, in clinical practice, ramucirumab monotherapy is sometimes used as third- or later-line treatment for AGC refractory to fluoropyrimidine and taxanes. | Retrospective observational study of salvage line ramucirumab monotherapy for patients with advanced gastric cancer